Development of Novel Pharmaceutical Forms of the Marine Bioactive Pigment Echinochrome A Enabling Alternative Routes of Administration
-
Published:2023-04-18
Issue:4
Volume:21
Page:250
-
ISSN:1660-3397
-
Container-title:Marine Drugs
-
language:en
-
Short-container-title:Marine Drugs
Author:
Kikionis Stefanos1ORCID, Papakyriakopoulou Paraskevi2ORCID, Mavrogiorgis Panagiotis1, Vasileva Elena A.3ORCID, Mishchenko Natalia P.3ORCID, Fedoreyev Sergey A.3ORCID, Valsami Georgia2ORCID, Ioannou Efstathia1ORCID, Roussis Vassilios1ORCID
Affiliation:
1. Section of Pharmacognosy and Chemistry of Natural Products, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece 2. Section of Pharmaceutical Technology, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15784 Athens, Greece 3. Laboratory of the Chemistry of Natural Quinonoid Compounds of the G. B. Elyakov Pacific Institute of Bioorganic Chemistry, Far-Eastern Branch of the Russian Academy of Science, Prospect 100 let Vladivostoku, 159, 690022 Vladivostok, Russia
Abstract
Echinochrome A (EchA), a marine bioactive pigment isolated from various sea urchin species, is the active agent of the clinically approved drug Histochrome®. EchA is currently only available in the form of an isotonic solution of its di- and tri-sodium salts due to its poor water solubility and sensitivity to oxidation. Electrospun polymeric nanofibers have lately emerged as promising drug carriers capable of improving the dissolution and bioavailability of drugs with limited water solubility. In the current study, EchA isolated from sea urchins of the genus Diadema collected at the island of Kastellorizo was incorporated in electrospun micro-/nanofibrous matrices composed of polycaprolactone and polyvinylpyrrolidone in various combinations. The physicochemical properties of the micro-/nanofibers were characterized using SEM, FT-IR, TGA and DSC analyses. The fabricated matrices exhibited variable dissolution/release profiles of EchA, as evidenced in in vitro experiments using gastrointestinal-like fluids (pH 1.2, 4.5 and 6.8). Ex vivo permeability studies using the EchA-loaded micro-/nanofibrous matrices showed an increased permeation of EchA across the duodenum barrier. The results of our study clearly show that electrospun polymeric micro-/nanofibers represent promising carriers for the development of new pharmaceutical formulations with controlled release, as well as increased stability and solubility of EchA, suitable for oral administration, while offering the potential for targeted delivery.
Funder
MARINOVA BioNP Russian Science Foundation
Subject
Drug Discovery,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Pharmaceutical Science
Reference57 articles.
1. Vasileva, E.A., Mishchenko, N.P., Tran, V.T.T., Vo, H.M.N., and Fedoreyev, S.A. (2021). Spinochrome identification and quantification in Pacific Sea urchin shells, coelomic fluid and eggs using HPLC-DAD-MS. Mar. Drugs, 19. 2. Histochrome: A new original domestic drug;Mishchenko;Pharm. Chem. J.,2003 3. Elyakov, G.B., Maximov, O.B., Mischenko, N.P., Koltsova, E.A., Fedoreev, S.A., Glebko, L.I., Krasovskaya, N.P., and Artjukov, A.A. (2007). Drug Preparation “Histochrome” for Treating Acute Myocardial Infarction and Ischemic Heart Diseases. (EP1121930B1), European Patent. 4. Elyakov, G.B., Maximov, O.B., Mischenko, N.P., Koltsova, E.A., Fedoreev, S.A., Glebko, L.I., Krasovskaya, N.P., and Artjukov, A.A. (2002). Histochrome and Its Therapeutic Use in Acute Myocardial Infarction and Ischemic Heart Disease. (US6410601B2), U.S. Patent. 5. Elyakov, G.B., Maximov, O.B., Mischenko, N.P., Koltsova, E.A., Fedoreev, S.A., Glebko, L.I., Krasovskaya, N.P., and Artjukov, A.A. (2004). Composition Comprising Di-and Trisodium Salts of Echinochrome for Treating Ocular Conditions. (EP1121929B1), European Patent.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|